www.bbc.co.uk
Saliva test may turn tide on prostate cancer claim scientists
Analysing DNA in saliva can identify men at the greatest risk of prostate cancer
#ProstateCancer is an active hashtag on Bluesky. In the last 30 days, 77 people shared 133 posts with it — around 4 a day. Activity is up 8% versus the previous week, peaking on Jul 11 with 10 posts.
Tags most often used together with #ProstateCancer.
www.bbc.co.uk
Saliva test may turn tide on prostate cancer claim scientists
Analysing DNA in saliva can identify men at the greatest risk of prostate cancer
bit.ly
Travel writer takes an unexpected cancer journey
After years of guiding others on their travels, Rick Steves, a travel writer and television host based in Edmonds, Wash., took an unexpected detour after getting diagnosed with prostate cancer.
prostatecanceruk.org
Check your risk in 30 seconds | Prostate Cancer UK
It's the most common cancer in men, but most men with early prostate cancer don't have symptoms. Find out about your risk now.
www.urologytimes.com
TikTok, social media does more harm than good for prostate cancer education
Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
scim.ag
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer
Targeting a cell stress response is synthetic lethal with loss of p53 in prostate cancer cells.
www.onclive.com
Dr Thompson on 5-ARIs for Active Surveillance in Prostate Cancer | OncLive
Ian M. Thompson Jr, MD, MBA, discusses the potential role of 5-ARIs such as finasteride in prostate cancer.
www.thelancet.com
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Combining 177Lu-PSMA-617 with ADT plus ARPI prolonged radiographic progression-free survival in patients with PSMA-positive metastatic APMN/S prostate cancer. Although adverse events were more frequen...
ascopubs.org
Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
This guideline has been updated.This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates.Living guidelines are developed for selected...
dlvr.it
ASCO_GU_ 2025_Social_Media_Report.pdf
drive.google.com/file/d/1Q1DrPio5c6P4F3VeL-5b3UCSo7DR9hXm/view
agentictribune.com
Radioligand 177Lu-PSMA-617 Delays Radiographic Progression in PSMA-Positive Hormone-Sensitive Metastatic Prostate Cancer, Phase 3 Trial Shows
Phase 3 PSMAddition trial found 177Lu‑PSMA‑617 added to hormonal therapy reduced risk of radiographic progression in PSMA‑positive mHSPC.
www.onclive.com
Dr Morris on the FDA Approval of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mHSPC | OncLive
Michael J. Morris, MD, discusses the significance of the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.